Incannex share price pops 9% on FDA news

The medicinal cannabis drug development company came out with some positive developments from its FDA meeting…

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Incannex shares hit an intraday high of 51 cents, but have since fallen a touch to 49.5 cents, up 8.79%
  • The company received positive notes from its pre-IND meeting with the FDA, with animal studies not required for IHL-42X
  • Incannex will now look at the adjustment of clinical trial designs to open an IND

The Incannex Healthcare Ltd (ASX: IHL) share price is soaring during mid-afternoon trade.

This follows the company's positive pre-investigational new drug application (pre-IND) meeting with the United States Food and Drug Administration (FDA).

At the time of writing, the healthcare company's shares are trading at 49.5 cents, up 8.79%.

FDA responds to IHL-42X pathway

According to the company's announcement, Incannex reported it received positive feedback from the FDA pre-IND meeting regarding the regulatory pathway for its IHL-42X.

Incannex's IHL-42X is a novel therapy that comprises dronabinol and acetazolamide. The medical therapy is targeted for the potential treatment of obstructive sleep apnoea (OSA) in adults.

In February, Incannex submitted a pre-IND meeting package and meeting request to the FDA. This included an overview of the development program and questions relating to regulatory requirements for opening an IND application.

To conduct clinical trials for any medical product in the United States, an IND must be opened.

The FDA provided "guidance on Incannex's proposed long-term development strategy, as well as specific parameters to demonstrate safety and efficacy in phase 2 and 3 pivotal studies", the company said.

Furthermore, the FDA agreed that Incannex doesn't need to conduct studies in animals for opening an IND for IHL-42X. This will save time and cost to the company which can now proceed with the adjustment of clinical trial designs to open an IND.

What did management say?

Incannex chief scientific officer Dr Mark Bleackley welcomed the feedback, saying:

The FDA's interest in IHL-42X as a potential therapy for OSA was extremely encouraging.

…The agency's responses to the specific questions we posed allow us to revise our clinical trial protocols, to ensure that we are running highly efficient studies that generate the type and amount of data the FDA will require in a future marketing application.

The results from the pre-IND meeting will shape the IHL-42X development program over the coming months.

Incannex share price snapshot

Over the past 12 months, the Incannex share price has rocketed by around 83% in value.

However, year to date, its shares are down 20%.

The company's shares reached a multi-year high of 75.5 cents in March, before giving up their gains.

On valuation metrics, Incannex has a market capitalisation of around $633 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »